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CDC Recommendations for Influenza Antiviral Medications Remain Unchanged
A recent review of randomized clinical trial data for the influenza neuraminidase inhibitor 
antiviral medications, and two related commentaries, raised questions about the value of 
antiviral medications for the prevention and treatment of influenza. On February 7, 2012, 
the Centers for Disease Control and Prevention (CDC) posted a "Have You Heard?" piece in 
response. The CDC response states "After careful consideration of all available evidence,
CDC guidance on the use of antiviral medications remains unchanged." CDC continues to 
recommend the use of neuraminidase inhibitor antiviral drugs (oral oseltam ivir and inhaled 
zanamivir) as an important adjunct in the prevention and treatment of influenza.
These recommendations emphasize early antiviral treatment as soon as possible for 
patients who are severely ill and for those who are at greatest risk for complications from 
influenza.
Patients who should receive early antiviral treatment include:
• Hospitalized patients with suspected or confirmed influenza;
• Persons with severe or progressive illness;
• Outpatients who are at high risk for influenza complications (for example, young 
children, people 65 and older, pregnant women, and persons with certain underlying 
chronic medical conditions) (For a full list of people at high risk of influenza 
complications, see: http://www.cdc.gov/flu/about/disease/high risk.htm) : and
• Persons with uncomplicated influenza who are not in a high risk group and who 
present within 48 hours of illness onset. These persons can be treated with antiviral 
medications based upon clinical judgment, because reviews of RCTs and 
observational studies have found consistent clinical benefit of early oseltam ivir 
treatment in reducing the risk of lower respiratory tract complications such as those 
requiring antibiotics.
CDC estimates that influenza virus infections in the United States result in an average of 
more than 200,000 related hospitalizations and 3,300-49,000 deaths each year, depending 
upon the severity of the influenza season. Annual influenza vaccination of all persons aged 6 
months and older is recommended, and is the best way to prevent influenza. However, 
available evidence for seasonal influenza and 2009 pandemic H1N1 consistently indicates 
that antiviral treatment, when initiated as soon as possible, can have clinical and public 
health benefit in reducing severe outcomes of influenza. Therefore, neuraminidase inhibitor 
antiviral medications continue to be recommended for treatment of influenza.
The full CDC response is available at:
http://www.cdc.gov/media/haveyouheard/stories/Influenza antiv iral.htm l.
For a summary of CDC antiviral guidance for the 2011-2012 influenza season see: 
http://www.cdc.gov/flu/pdf/professionals/antivirals/clin ician-antivirals-2011.pdf
For the full document outlining ACIP and CDC recommendations and references supporting 
the statements in the "Have You Heard," CDC response, see "Antiviral Agents for the 
Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory 
Committee on Immunization Practices (ACIP)" at: 
http://www.cdc.gov/mmwr/pdf/rr/rr6001.pdf
To read the review of randomized clinical trial data for the influenza neuraminidase inhibitor 
antiviral medications and related commentaries, see:
• The Cochrane Library's "Neuram inidase inhibitors for influenza: methods change, 
principles don't" at:
http://www.thecochranelibrary.com/details/editorial/1442857/Neuram inidase-
inhibitors-for-influenza-methods-chanae-principles-dont.htm l
• The British Medical Journal's "Rethinking credible evidence synthesis" at: 
http://www.bm i.com/content/344/bm i.d7898
• The British Medical Journal's "Questions remain over safety and effectiveness of 
oseltam ivir" at: h ttp: //www.bm i.com/content/344/bm i.e467
The Centers for Disease Control and Prevention (CDC) protects people's health and safety 
by preventing and controlling diseases and injuries; enhances health decisions by providing 
credible information on critical health issues; and promotes healthy living through strong 
partnerships with local, national and international organizations.
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